By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

China, India and the US will have the world’s largest populations of adults living with overweight and obesity by 2050, ...

A number of sessions on the second day of IPWatchdog LIVE examined the state of U.S. IP policy and the potential for change ...

Lilly knew from a young age that she wanted to work with children, and wasted no time in getting her career started.

A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...

Brands That Matter panel to examine Purdue-led pharmaceutical transformations ...

CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...